melatonin

EXPRESSION OF CONCERN: Melatonin Protects Against Diabetic Cardiomyopathy Through Mst1/Sirt3 Signaling.

RETRACTION: The Dual Roles of Melatonin Biosynthesis Enzymes in the Coordination of Melatonin Biosynthesis and Autophagy in Cassava.

Y. Wei, Y. Bai, X. Cheng, B. Zhu, R. J. Reiter, and H. Shi, "The Dual Roles of Melatonin Biosynthesis Enzymes in the Coordination of Melatonin Biosynthesis and Autophagy in Cassava," Journal of Pineal Research 69, no. 1 (2020): e12652, https://doi.org/10.1111/jpi.12652. The above article, published online on 23 March 2020 in Wiley Online Library (wileyonlinelibrary.com), has been retracted by agreement between the journal Editor-in-Chief, Gianluca Tosini; and John Wiley & Sons Ltd. A report on PubPeer [1] indicated that the pTRV and pTRV-MeASMT3 images in Figure 3D had been duplicated and presented as different samples in Figure 7B following rotation and further alteration. Additionally, several samples presented in Figure 4 contained overlapping or duplicated images. These concerns were confirmed by the publisher. The authors responded to an inquiry by the publisher and reported that an additional image duplication had occurred in between Figures 6C and 7C, in addition to the other errors. They reported that the duplications were due to mistakes during manuscript preparation. While the authors presented original as well as repeat data with the intention of correcting these errors, the authors did not provide a satisfactory explanation for the evidence of image rotation and alteration of images between Figures 3 and 7. Therefore, the publisher and the editor have lost confidence in the results and the conclusions, and the article must be retracted. The authors agree with the retraction.

Dexmedetomidine-flurbiprofen axetil-based opioid-free analgesia attenuates postoperative melatonin suppression and improves sleep quality after thyroidectomy: a randomized controlled trial.

Guo Rui R, Luo Xin X, Chen Li L, Rao Pan-Guo PG et al.

To determine whether an opioid-free patient-controlled intravenous analgesia (PCIA) regimen based on dexmedetomidine and flurbiprofen axetil improves postoperative sleep quality and affects nocturnal melatonin secretion compared to a sufentanil-based regimen in patients undergoing thyroidectomy. In this prospective, randomized, double-blind controlled trial, 96 patients undergoing thyroidectomy were randomly assigned to receive either opioid-free PCIA (dexmedetomidine, flurbiprofen axetil, and ondansetron) or opioid PCIA (sufentanil and ondansetron). PCIA was initiated 5 min before the end of surgery. The primary outcome was postoperative sleep quality, assessed using the Richards-Campbell Sleep Questionnaire (RCSQ). Secondary outcomes included urinary 6-sulfatoxymelatonin (6-SMT) excretion normalized to creatinine, detailed sleep parameters, anxiety levels, pain intensity, sedation levels, and postoperative adverse events. Assessments of sleep quality, urinary 6-SMT excretion, and anxiety levels were performed preoperatively (T0) and on postoperative days 1 (T1) and 2 (T2). Pain intensity (assessed by the Visual Analog Scale, VAS) and sedation levels (assessed using the Ramsay Sedation Scale) were measured at postoperative hours 1, 6, 24, and 48. Patients in the opioid-free group exhibited significantly higher RCSQ scores at T1 and T2, indicating improved postoperative sleep quality (all P < 0.001). Correspondingly, urinary 6-SMT excretion was significantly higher in the opioid-free group at both postoperative time points (P < 0.001), suggesting better preservation of nocturnal melatonin secretion. Detailed sleep parameters showed shorter sleep latency, fewer nocturnal awakenings, and longer total sleep time in the opioid-free group (all P < 0.01). Anxiety levels were significantly lower in the opioid-free group (P < 0.001). Postoperative pain intensity and sedation levels were comparable between groups at all time points (all P > 0.05). The incidences of nausea, vomiting, and pruritus were significantly reduced in the opioid-free group (P < 0.05). An opioid-free PCIA regimen based on dexmedetomidine and flurbiprofen axetil provides non-inferior postoperative analgesia while attenuating postoperative melatonin suppression, improving sleep quality, reducing anxiety, and decreasing opioid-related adverse events. This opioid-sparing strategy may represent an effective approach to enhance postoperative recovery after thyroidectomy. https://www.chictr.org.cn, identifier ChiCTR2400079949. 01/17/2024.

Melatonin-Zinc MOFs Antimycotic, Molecular, and Antioxidant Protective Effects of Hepatic, Renal, and Testicular Dysfunctions Induced by Aflatoxin B1 in Rats.

Aly Mohamed S MS, Soliman Mona M H MMH, Balabel Esraa A EA, Abdelhameed Reda M RM et al.

Aflatoxin B1 causes renal, hepatic, and reproductive disorders. To investigate the protective effects of melatonin-zinc metal-organic frameworks (Mt-Zn-MOFs) nanoparticles against renal, hepatic, and reproductive toxicity induced by aflatoxins B1, male Sprague-Dawley rats (n = 40) were equally divided into control, Mt-Zn-MOFs, aflatoxins, and Mt-Zn-MOFs + aflatoxins groups. Blood and tissue samples were collected from the livers, kidneys, and testicles. Luteinizing hormone (LH), testosterone, estradiol (E2), interleukin-β (IL-β), transforming growth factor-β (TGF-β), superoxide dismutase (SOD), catalase (CAT), glutathione peroxidase (GPx), total antioxidants (TAC), nitric oxide (NO), AST, ALT, and creatinine were measured. Hepatic DNA fragmentation and the expression of CRAT, CYP39A1, and JunB genes were determined. Mt-Zn-MOFs have more antimycotic effects against A. flavus than A. parasiticus, with MIC and MFC of 3.125 and 6.25 mg/mL for A. flavus and 12.5 and 25 mg/mL for A. parasiticus, and 6.25 mg/mL inhibited A. flavus and A. parasiticus sporulation. Mt-Zn-MOFs rats had high (p < 0.001) testosterone, LH, E2, glucose, but low (p < 0.01) SOD, total proteins, albumin, globulin, AST, and ALT, compared to controls. Mt-Zn-MOFs-aflatoxin group had lower (p < 0.01) LH, SOD, GPx, total proteins, globulin, glucose, TGF-β (p < 0.022), DNA fragmentation, and the expressions of JunB, CYP39A1, and CRAT, but high (p < 0.01) NO, CAT, and total cholesterol than aflatoxin-treated rats. Mt-Zn-MOFs protected the liver, kidney, and spermatogenesis to a large extent. Mt-Zn-MOFs maintained normal testicular, hepatic, and renal histopathology in the aflatoxin treatment. Regardless, aflatoxin caused severe renal toxicity, Mt-Zn-MOFs reversed the effects of toxins and restored their normality, and are recommended to treat aflatoxicosis and mycotic infections.